MX2018013863A - Terapias combinadas que usan derivados de indazolilbenzamida para el tratamiento del cancer. - Google Patents

Terapias combinadas que usan derivados de indazolilbenzamida para el tratamiento del cancer.

Info

Publication number
MX2018013863A
MX2018013863A MX2018013863A MX2018013863A MX2018013863A MX 2018013863 A MX2018013863 A MX 2018013863A MX 2018013863 A MX2018013863 A MX 2018013863A MX 2018013863 A MX2018013863 A MX 2018013863A MX 2018013863 A MX2018013863 A MX 2018013863A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
indazolylbenzamide
derivatives
combination therapies
Prior art date
Application number
MX2018013863A
Other languages
English (en)
Inventor
O M Orlemans Everardus
Original Assignee
Esanex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esanex Inc filed Critical Esanex Inc
Publication of MX2018013863A publication Critical patent/MX2018013863A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a terapias combinadas útiles en el tratamiento y/o en la prevención del cáncer.
MX2018013863A 2016-05-18 2017-05-18 Terapias combinadas que usan derivados de indazolilbenzamida para el tratamiento del cancer. MX2018013863A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662338370P 2016-05-18 2016-05-18
PCT/US2017/033229 WO2017201226A1 (en) 2016-05-18 2017-05-18 Combination therapies using indazolylbenzamide derivatives for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2018013863A true MX2018013863A (es) 2019-08-12

Family

ID=58794187

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013863A MX2018013863A (es) 2016-05-18 2017-05-18 Terapias combinadas que usan derivados de indazolilbenzamida para el tratamiento del cancer.

Country Status (9)

Country Link
US (1) US20190134003A1 (es)
EP (1) EP3458048A1 (es)
JP (1) JP2019516794A (es)
KR (1) KR20190009346A (es)
CN (1) CN109152761A (es)
AU (1) AU2017268356A1 (es)
CA (1) CA3022882A1 (es)
MX (1) MX2018013863A (es)
WO (1) WO2017201226A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20104994B (en) * 2005-02-25 2010-05-25 Serenex Inc Tetrahydroindolone and tetrahydroindazolone derivatives
US20120064175A1 (en) * 2010-05-20 2012-03-15 Synta Pharmaceuticals Corp. HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients

Also Published As

Publication number Publication date
WO2017201226A1 (en) 2017-11-23
EP3458048A1 (en) 2019-03-27
CN109152761A (zh) 2019-01-04
JP2019516794A (ja) 2019-06-20
KR20190009346A (ko) 2019-01-28
US20190134003A1 (en) 2019-05-09
AU2017268356A1 (en) 2018-11-15
CA3022882A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
PT3600281T (pt) Terapia combinada para o tratamento ou prevenção de tumores
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
ZA201900960B (en) Methods and compositions for the treatment of cancer
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
IL280587B (en) Fluorocitidine derivatives and their preparations for use in cancer treatment
PH12016501838A1 (en) Compounds and their methods of use
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
IL272147A (en) Methods and preparations for the treatment of cancer
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation
MX2019003002A (es) Terapias de combinacion que usan derivados de indazolilbenzamida para el tratamiento del cancer.
MX2018013863A (es) Terapias combinadas que usan derivados de indazolilbenzamida para el tratamiento del cancer.
WO2019028012A3 (en) METHODS OF USING PEMBROLIZUMAB AND TREBANANIB